Mr. Davenport is a Managing Director at SK Capital and plays a leading role in all aspects of the firm’s investment strategy. He focuses on both the healthcare and specialty chemicals industries and currently serves as Chairman of Halo Pharmaceutical, AEB Group, Noramco, Inc. and Tasmanian Alkaloids and as a member of the Board of Directors of Archroma. He previously served on the Board of Directors of IBA Molecular. He joined the firm in 2010. Prior to SK Capital, Mr. Davenport was a Principal at Arsenal Capital Partners where he co-led Arsenal’s healthcare investing efforts and served on the firm’s Operating and Investment Committees. Mr. Davenport’s professional career began in a general management role with CB Richard Ellis/Whittier Partners, where his leadership positions included Director of Business Strategy and Development. Mr. Davenport was previously the Chairman of Charter Brokerage and previously served on the boards of Bend Research, IRIX Pharmaceuticals, Scientific Protein Laboratories, Priority Solutions, and Innovative Medical Device Solutions. Mr. Davenport graduated magna cum laude with a B.A. in History from Amherst College and has an M.B.A. from the Tuck School of Business at Dartmouth College.
Interested in Business Management.